Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113

Clin Infect Dis. 2020 Feb 3;70(4):687-691. doi: 10.1093/cid/ciz486.

Abstract

Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).

Keywords: adolescents; bone mineral density; men who have sex with men; preexposure prophylaxis; tenofovir disoproxil fumarate.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents* / pharmacology
  • Anti-HIV Agents* / therapeutic use
  • Bone Density
  • Emtricitabine / pharmacology
  • Emtricitabine / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Homosexuality, Male
  • Humans
  • Male
  • Pre-Exposure Prophylaxis*
  • Sexual and Gender Minorities*
  • Tenofovir / pharmacology
  • Tenofovir / therapeutic use
  • Young Adult

Substances

  • Anti-HIV Agents
  • Tenofovir
  • Emtricitabine

Associated data

  • ClinicalTrials.gov/NCT01772823
  • ClinicalTrials.gov/NCT01769456